NV-387 by NanoViricides: A Revolutionary Therapy That Could Prevent Cancer Recurrence While Battling Deadly Viruses—Phase II Trials Underway!
NanoViricides, Inc. (NYSE American: NNVC) is at the forefront of a potential medical revolution with its lead drug NV-387, now advancing into Phase II clinical trials. NV-387 is not just a powerful broad-spectrum antiviral—it may also prevent the recurrence of metastatic cancer in patients in remission!
Research shows that viral infections, including COVID-19, Influenza, RSV, and measles, can awaken dormant cancer cells, driving metastasis. NV-387 works on two fronts: it attacks the virus while reducing harmful inflammation, particularly IL-6 cytokines, which studies link to cancer cell reactivation.
In preclinical studies, NV-387 protected lungs from lethal viral infections while dramatically lowering inflammatory markers, outperforming existing antivirals like Tamiflu and Xofluza. This means NV-387 has unique first-in-class potential, combining lifesaving antiviral efficacy with groundbreaking cancer-prevention effects.
The implications for patients and the market are massive. With viral infections surging globally and no therapy currently addressing both viral threats and the risk of metastatic cancer recurrence,
NNVC's NV-387 is positioned to meet a critical unmet medical need.
NanoViricides' exclusive nanoviricide™ platform technology ensures viruses cannot escape, even as new variants emerge, giving the drug a rare competitive edge. This is a company pioneering dual-benefit therapies that could transform antiviral treatment and cancer care simultaneously.
With Phase II trials on the horizon, the clinical, commercial, and societal potential of NV-387 is extraordinary.
Discover how NV-387's dual mechanism and unmatched preclinical data make NanoViricides a company poised for transformative impact—financially and medically.
This message is a PAID ADVERTISEMENT for NanoViricides, Inc (NYSE: NNVC) from Interactive Offers. StockEarnings, Inc. has received a fixed fee of $7000 from Interactive Offers for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between September 2, 2025 and September 5, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc (NYSE: NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc (NYSE: NNVC) on Smallcaps Daily website for additional information about the relationship between Interactive Offers and NanoViricides, Inc (NYSE: NNVC).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.
StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
